Identification of a signature of histone modifiers in kidney renal clear cell carcinoma
Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KI...
Gespeichert in:
Veröffentlicht in: | Aging (Albany, NY.) NY.), 2024-06, Vol.16 (12), p.10489-10511 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 10511 |
---|---|
container_issue | 12 |
container_start_page | 10489 |
container_title | Aging (Albany, NY.) |
container_volume | 16 |
creator | Huang, Yongming Yang, Zhongsheng Tang, Ying Chen, Hua Liu, Tairong Peng, Guanghua Huang, Xin He, Xiaolong Mei, Ming Du, Chuance |
description | Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC. |
doi_str_mv | 10.18632/aging.205944 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3070794640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</originalsourceid><addsrcrecordid>eNpVkc1vGyEQxVGVqvnqsdeKYy7rwvKxcKqqKG0tRcolVY5ovAwOyS64sI7k_77rOIlSLgyan97w5hHyhbMFN1q032Ad03rRMmWl_EBOuJWqkcrYo3f1MTmt9YExrZTUn8ixMPNRXJ2Qu6XHNMUQe5hiTjQHCrTGdYJpW3D_vI91ygnpmP2MYak0JvoYfcIdLZhgoP2AUGiPw1xC6WPKI5yTjwGGip9f7jPy5-fV7eXv5vrm1_Lyx3XTc2NlgyoIa2ww3nRMW679KnBleqVbCMi8BtXZFaD0AoTGlUDWBQUYtDehFVacke8H3c12NaLvZzMFBrcpcYSycxmi-7-T4r1b5yfHeSu0YGZWuHhRKPnvFuvkxlj3ZiBh3lYnWMc6K7VkM9oc0L7kWguGtzmcuec03HMa7pDGzH99_7k3-nX94h9Zx4in</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070794640</pqid></control><display><type>article</type><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</creator><creatorcontrib>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</creatorcontrib><description>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</description><identifier>ISSN: 1945-4589</identifier><identifier>EISSN: 1945-4589</identifier><identifier>DOI: 10.18632/aging.205944</identifier><identifier>PMID: 38888515</identifier><language>eng</language><publisher>United States: Impact Journals</publisher><subject>Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - metabolism ; Epigenesis, Genetic ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Histones - genetics ; Histones - metabolism ; Humans ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - genetics ; Prognosis ; Research Paper ; Transcriptome</subject><ispartof>Aging (Albany, NY.), 2024-06, Vol.16 (12), p.10489-10511</ispartof><rights>Copyright: © 2024 Huang et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236308/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236308/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38888515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yongming</creatorcontrib><creatorcontrib>Yang, Zhongsheng</creatorcontrib><creatorcontrib>Tang, Ying</creatorcontrib><creatorcontrib>Chen, Hua</creatorcontrib><creatorcontrib>Liu, Tairong</creatorcontrib><creatorcontrib>Peng, Guanghua</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>He, Xiaolong</creatorcontrib><creatorcontrib>Mei, Ming</creatorcontrib><creatorcontrib>Du, Chuance</creatorcontrib><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><title>Aging (Albany, NY.)</title><addtitle>Aging (Albany NY)</addtitle><description>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - metabolism</subject><subject>Epigenesis, Genetic</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Histones - genetics</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - genetics</subject><subject>Prognosis</subject><subject>Research Paper</subject><subject>Transcriptome</subject><issn>1945-4589</issn><issn>1945-4589</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1vGyEQxVGVqvnqsdeKYy7rwvKxcKqqKG0tRcolVY5ovAwOyS64sI7k_77rOIlSLgyan97w5hHyhbMFN1q032Ad03rRMmWl_EBOuJWqkcrYo3f1MTmt9YExrZTUn8ixMPNRXJ2Qu6XHNMUQe5hiTjQHCrTGdYJpW3D_vI91ygnpmP2MYak0JvoYfcIdLZhgoP2AUGiPw1xC6WPKI5yTjwGGip9f7jPy5-fV7eXv5vrm1_Lyx3XTc2NlgyoIa2ww3nRMW679KnBleqVbCMi8BtXZFaD0AoTGlUDWBQUYtDehFVacke8H3c12NaLvZzMFBrcpcYSycxmi-7-T4r1b5yfHeSu0YGZWuHhRKPnvFuvkxlj3ZiBh3lYnWMc6K7VkM9oc0L7kWguGtzmcuec03HMa7pDGzH99_7k3-nX94h9Zx4in</recordid><startdate>20240617</startdate><enddate>20240617</enddate><creator>Huang, Yongming</creator><creator>Yang, Zhongsheng</creator><creator>Tang, Ying</creator><creator>Chen, Hua</creator><creator>Liu, Tairong</creator><creator>Peng, Guanghua</creator><creator>Huang, Xin</creator><creator>He, Xiaolong</creator><creator>Mei, Ming</creator><creator>Du, Chuance</creator><general>Impact Journals</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240617</creationdate><title>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</title><author>Huang, Yongming ; Yang, Zhongsheng ; Tang, Ying ; Chen, Hua ; Liu, Tairong ; Peng, Guanghua ; Huang, Xin ; He, Xiaolong ; Mei, Ming ; Du, Chuance</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1894-e5f3989f8d8706916dbf158c562afe0d6a579bae4d3a36eb3e07f5aef6d8f2393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - metabolism</topic><topic>Epigenesis, Genetic</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Histones - genetics</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - genetics</topic><topic>Prognosis</topic><topic>Research Paper</topic><topic>Transcriptome</topic><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yongming</creatorcontrib><creatorcontrib>Yang, Zhongsheng</creatorcontrib><creatorcontrib>Tang, Ying</creatorcontrib><creatorcontrib>Chen, Hua</creatorcontrib><creatorcontrib>Liu, Tairong</creatorcontrib><creatorcontrib>Peng, Guanghua</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>He, Xiaolong</creatorcontrib><creatorcontrib>Mei, Ming</creatorcontrib><creatorcontrib>Du, Chuance</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Aging (Albany, NY.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yongming</au><au>Yang, Zhongsheng</au><au>Tang, Ying</au><au>Chen, Hua</au><au>Liu, Tairong</au><au>Peng, Guanghua</au><au>Huang, Xin</au><au>He, Xiaolong</au><au>Mei, Ming</au><au>Du, Chuance</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of a signature of histone modifiers in kidney renal clear cell carcinoma</atitle><jtitle>Aging (Albany, NY.)</jtitle><addtitle>Aging (Albany NY)</addtitle><date>2024-06-17</date><risdate>2024</risdate><volume>16</volume><issue>12</issue><spage>10489</spage><epage>10511</epage><pages>10489-10511</pages><issn>1945-4589</issn><eissn>1945-4589</eissn><abstract>Kidney renal clear cell carcinoma (KIRC) is a cancer that is closely associated with epigenetic alterations, and histone modifiers (HMs) are closely related to epigenetic regulation. Therefore, this study aimed to comprehensively explore the function and prognostic value of HMs-based signature in KIRC. HMs were first obtained from top journal. Then, the mRNA expression profiles and clinical information in KIRC samples were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Cox regression analysis and least absolute shrinkage and selection operator (Lasso) analysis were implemented to find prognosis-related HMs and construct a risk model related to the prognosis in KIRC. Kaplan-Meier analysis was used to determine prognostic differences between high- and low-risk groups. Immune infiltration and drug sensitivity analysis were also performed between high- and low-risk groups. Eventually, 8 HMs were successfully identified for the construction of a risk model in KIRC. The results of the correlation analysis between risk signature and the prognosis showed HMs-based signature has good prognostic value in KIRC. Results of immune analysis of risk models showed there were significant differences in the level of immune cell infiltration and expression of immune checkpoints between high- and low-risk groups. The results of the drug sensitivity analysis showed that the high-risk group was more sensitive to several chemotherapeutic agents such as Sunitinib, Tipifarnib, Nilotinib and Bosutinib than the low-risk group. In conclusion, we successfully constructed HMs-based prognostic signature that can predict the prognosis of KIRC.</abstract><cop>United States</cop><pub>Impact Journals</pub><pmid>38888515</pmid><doi>10.18632/aging.205944</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1945-4589 |
ispartof | Aging (Albany, NY.), 2024-06, Vol.16 (12), p.10489-10511 |
issn | 1945-4589 1945-4589 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11236308 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - metabolism Epigenesis, Genetic Gene Expression Profiling Gene Expression Regulation, Neoplastic Histones - genetics Histones - metabolism Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Prognosis Research Paper Transcriptome |
title | Identification of a signature of histone modifiers in kidney renal clear cell carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T04%3A06%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20a%20signature%20of%20histone%20modifiers%20in%20kidney%20renal%20clear%20cell%20carcinoma&rft.jtitle=Aging%20(Albany,%20NY.)&rft.au=Huang,%20Yongming&rft.date=2024-06-17&rft.volume=16&rft.issue=12&rft.spage=10489&rft.epage=10511&rft.pages=10489-10511&rft.issn=1945-4589&rft.eissn=1945-4589&rft_id=info:doi/10.18632/aging.205944&rft_dat=%3Cproquest_pubme%3E3070794640%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070794640&rft_id=info:pmid/38888515&rfr_iscdi=true |